1. Home
  2. RETO vs BTAI Comparison

RETO vs BTAI Comparison

Compare RETO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RETO

ReTo Eco-Solutions Inc.

HOLD

Current Price

$1.32

Market Cap

21.9M

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$0.19

Market Cap

24.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RETO
BTAI
Founded
1999
2017
Country
China
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.9M
24.8M
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
RETO
BTAI
Price
$1.32
$0.19
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
1.1M
889.1K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.63
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$197.82
Revenue Next Year
N/A
$910.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.70
52 Week High
$4.66
$4.29

Technical Indicators

Market Signals
Indicator
RETO
BTAI
Relative Strength Index (RSI) 38.13 21.60
Support Level $0.62 N/A
Resistance Level $2.04 $1.26
Average True Range (ATR) 0.44 0.10
MACD -0.01 -0.05
Stochastic Oscillator 30.00 1.26

Price Performance

Historical Comparison
RETO
BTAI

About RETO ReTo Eco-Solutions Inc.

ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Equipment and technical service segment, and Craft beer segment. The company earns its revenue from the Equipment and technical service segment. Geographically, it derives a majority of its revenue from China.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: